Examining the Association Between Exposome Score for Schizophrenia and Functioning in Schizophrenia, Siblings, and Healthy Controls: Results from the EUGEI Study

Background: A cumulative environmental exposure score for schizophrenia (exposome score for schizophrenia [ES-SCZ]) may provide potential utility for risk stratification and outcome prediction. Here, we investigated whether ES-SCZ was associated with functioning in patients with schizophrenia spectrum disorder, unaffected siblings, and healthy controls.

Methods: This cross-sectional sample consisted of 1,261 patients, 1,282 unaffected siblings, and 1,525 healthy controls. The Global Assessment of Functioning (GAF) scale was used to assess functioning. ES-SCZ was calculated based on our previously validated method. The association between ES-SCZ and the GAF dimensions (symptom and disability) was analyzed by applying regression models in each group (patients, siblings, and controls). Additional models included polygenic risk score for schizophrenia (PRS-SCZ) as a covariate.

Results: ES-SCZ was associated with the GAF dimensions in patients (symptom: B = -1.53, p-value = 0.001; disability: B = -1.44, p-value = 0.001), siblings (symptom: B = -3.07, p-value < 0.001; disability: B = -2.52, p-value < 0.001), and healthy controls (symptom: B = -1.50, p-value < 0.001; disability: B = -1.31, p-value < 0.001). The results remained the same after adjusting for PRS-SCZ. The degree of associations of ES-SCZ with both symptom and disability dimensions were higher in unaffected siblings than in patients and controls. By analyzing an independent dataset (the Genetic Risk and Outcome of Psychosis study), we replicated the results observed in the patient group.

Conclusions: Our findings suggest that ES-SCZ shows promise for enhancing risk prediction and stratification in research practice. From a clinical perspective, ES-SCZ may aid in efforts of clinical characterization, operationalizing transdiagnostic clinical staging models, and personalizing clinical management.

Citing Articles

Childhood Adversity Determines the Syndemic Effects of Violence, Substance Misuse, and Sexual Behavior on Psychotic Spectrum Disorder Among Men.

Zhang Y, Coid J Schizophr Bull. 2023; 50(3):684-694.

PMID: 38019938 PMC: 11059794. DOI: 10.1093/schbul/sbad165.

The biopsychosocial model of schizophrenia and cancer: Unraveling the etiopathogenesis of complex diseases.

Fiorillo A, Giordano A Eur Psychiatry. 2022; 65(1):e86.

PMID: 36517923 PMC: 9807452. DOI: 10.1192/j.eurpsy.2022.2349.

The Exposome Paradigm to Understand the Environmental Origins of Mental Disorders.

Erzin G, Guloksuz S Alpha Psychiatry. 2022; 22(4):171-176.

PMID: 36424935 PMC: 9590645. DOI: 10.5152/alphapsychiatry.2021.21307.

Estimating the Association Between Exposome and Psychosis as Well as General Psychopathology: Results From the ABCD Study.

Pries L, Moore T, Visoki E, Sotelo I, Barzilay R, Guloksuz S Biol Psychiatry Glob Open Sci. 2022; 2(3):283-291.

PMID: 36325038 PMC: 9616253. DOI: 10.1016/j.bpsgos.2022.05.005.

Exposome and Trans-syndromal Developmental Trajectories Toward Psychosis.

Barzilay R, Pries L, Moore T, Gur R, van Os J, Rutten B Biol Psychiatry Glob Open Sci. 2022; 2(3):197-205.

PMID: 36325037 PMC: 9616341. DOI: 10.1016/j.bpsgos.2022.05.001.

References

Schimmelmann B, Conus P, Cotton S, Kupferschmid S, McGorry P, Lambert M . Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. Eur Psychiatry. 2011; 27(6):463-9. DOI: 10.1016/j.eurpsy.2011.03.001. View

Pries L, Dal Ferro G, van Os J, Delespaul P, Kenis G, Lin B . Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. Epidemiol Psychiatr Sci. 2020; 29:e182. PMC: 7681168. DOI: 10.1017/S2045796020000943. View

Guloksuz S, van Os J . The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. Psychol Med. 2017; 48(2):229-244. DOI: 10.1017/S0033291717001775. View

Guloksuz S, Pries L, Have M, de Graaf R, van Dorsselaer S, Klingenberg B . Association of preceding psychosis risk states and non-psychotic mental disorders with incidence of clinical psychosis in the general population: a prospective study in the NEMESIS-2 cohort. World Psychiatry. 2020; 19(2):199-205. PMC: 7215054. DOI: 10.1002/wps.20755. View

Stone J, Fisher H, Major B, Chisholm B, Woolley J, Lawrence J . Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med. 2013; 44(3):499-506. DOI: 10.1017/S0033291713000883. View

Stilo S, Murray R . Non-Genetic Factors in Schizophrenia. Curr Psychiatry Rep. 2019; 21(10):100. PMC: 6745031. DOI: 10.1007/s11920-019-1091-3. View

Marsman A, Pries L, Have M, de Graaf R, van Dorsselaer S, Bak M . Do Current Measures of Polygenic Risk for Mental Disorders Contribute to Population Variance in Mental Health?. Schizophr Bull. 2020; 46(6):1353-1362. PMC: 7707067. DOI: 10.1093/schbul/sbaa086. View

Loh P, Danecek P, Palamara P, Fuchsberger C, Reshef Y, Finucane H . Reference-based phasing using the Haplotype Reference Consortium panel. Nat Genet. 2016; 48(11):1443-1448. PMC: 5096458. DOI: 10.1038/ng.3679. View

van Winkel R . Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry. 2010; 68(2):148-57. DOI: 10.1001/archgenpsychiatry.2010.152. View

10.

Pries L, van Os J, Have M, de Graaf R, van Dorsselaer S, Bak M . Association of Recent Stressful Life Events With Mental and Physical Health in the Context of Genomic and Exposomic Liability for Schizophrenia. JAMA Psychiatry. 2020; 77(12):1296-1304. PMC: 7711318. DOI: 10.1001/jamapsychiatry.2020.2304. View

11.

Sorensen H, Debost J, Agerbo E, Benros M, McGrath J, Mortensen P . Polygenic Risk Scores, School Achievement, and Risk for Schizophrenia: A Danish Population-Based Study. Biol Psychiatry. 2018; 84(9):684-691. DOI: 10.1016/j.biopsych.2018.04.012. View

12.

Gur R, Moore T, Rosen A, Barzilay R, Roalf D, Calkins M . Burden of Environmental Adversity Associated With Psychopathology, Maturation, and Brain Behavior Parameters in Youths. JAMA Psychiatry. 2019; 76(9):966-975. PMC: 6547104. DOI: 10.1001/jamapsychiatry.2019.0943. View

13.

Korver N, Quee P, Boos H, Simons C, de Haan L . Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int J Methods Psychiatr Res. 2012; 21(3):205-21. PMC: 6878383. DOI: 10.1002/mpr.1352. View

14.

Frank J, Lang M, Witt S, Strohmaier J, Rujescu D, Cichon S . Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Mol Psychiatry. 2014; 20(2):150-1. PMC: 4356742. DOI: 10.1038/mp.2014.56. View

15.

Kraan T, Velthorst E, Themmen M, Valmaggia L, Kempton M, McGuire P . Child Maltreatment and Clinical Outcome in Individuals at Ultra-High Risk for Psychosis in the EU-GEI High Risk Study. Schizophr Bull. 2017; 44(3):584-592. PMC: 5890491. DOI: 10.1093/schbul/sbw162. View

16.

van Os J, Rutten B, Myin-Germeys I, Delespaul P, Viechtbauer W, van Zelst C . Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull. 2014; 40(4):729-36. PMC: 4059449. DOI: 10.1093/schbul/sbu069. View

17.

Guloksuz S, van Os J, Rutten B . The Exposome Paradigm and the Complexities of Environmental Research in Psychiatry. JAMA Psychiatry. 2018; 75(10):985-986. DOI: 10.1001/jamapsychiatry.2018.1211. View

18.

Allardyce J, Leonenko G, Hamshere M, Pardinas A, Forty L, Knott S . Association Between Schizophrenia-Related Polygenic Liability and the Occurrence and Level of Mood-Incongruent Psychotic Symptoms in Bipolar Disorder. JAMA Psychiatry. 2017; 75(1):28-35. PMC: 5833541. DOI: 10.1001/jamapsychiatry.2017.3485. View

19.

Hunter S, Mora-Merchan J, Ortega R . The long-term effects of coping strategy use in victims of bullying. Span J Psychol. 2004; 7(1):3-12. DOI: 10.1017/s1138741600004704. View

20.

Maj M, van Os J, De Hert M, Gaebel W, Galderisi S, Green M . The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry. 2021; 20(1):4-33. PMC: 7801854. DOI: 10.1002/wps.20809. View